Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
AMVUTTRA Revenue	1.77B	970.45M	557.84M
AMVUTTRA Revenue Growth	82.78%	73.97%	494.74%
ONPATTRO Revenue	197.21M	252.86M	354.55M
ONPATTRO Revenue Growth	-22.01%	-28.68%	-36.42%
GIVLAARI Revenue	286.34M	255.87M	219.25M
GIVLAARI Revenue Growth	11.91%	16.70%	26.63%
OXLUMO Revenue	185.36M	167.05M	109.84M
OXLUMO Revenue Growth	10.96%	52.09%	57.40%
Total Product Revenue	2.44B	1.65B	1.24B
Total Product Revenue Growth	48.38%	32.60%	38.82%
Roche - Collaboration Revenue	373.94M	119.49M	337.80M
Roche - Collaboration Revenue Growth	212.95%	-64.63%	-
Regeneron Pharmaceuticals - Collaboration Revenue	136.78M	302.80M	100.47M
Regeneron Pharmaceuticals - Collaboration Revenue Growth	-54.83%	201.39%	14.37%
Novartis AG - Collaboration Revenue	-	79.76M	86.73M
Novartis AG - Collaboration Revenue Growth	-	-8.03%	100.95%
Other - Collaboration Revenue (Post-FY2022)	48.65M	8.18M	21.19M
Other - Collaboration Revenue (Post-FY2022) Growth	495.07%	-61.42%	442.03%
Total Collaboration Revenue	619.37M	510.22M	546.19M
Total Collaboration Revenue Growth	21.39%	-6.59%	304.84%
Royalty Revenue	148.04M	91.79M	40.63M
Royalty Revenue Growth	61.27%	125.91%	396.92%
Revenue (Other)	-559.37M	-510.22M	-546.19M
Revenue (Total)	3.21B	2.25B	1.83B
Revenue (Total) Growth	42.78%	22.97%	76.23%

Updated Sep 30, 2025. Data Source: Fiscal.ai.